The Future of Migraine Prevention and Treatment

This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.

Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.

Researchers set out to determine any differences between patients with benign recurrent vertigo, vestibular migraine, or Menière's disease.

This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.

Researchers outlined trends in treatment and management for patients presenting to the emergency department with headaches.

Worse cognitive performance was seen among children prior to migraine attack onset compared with those who never developed migraine.